Reviewed by Michael Gill, B. Sc.
25 Cholangiocarcinoma Clinical Trials Near Me
Top Hospitals for Cholangiocarcinoma Clinical Trials
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
11Active Trials
23All Time Trials for Cholangiocarcinoma
2000First Cholangiocarcinoma Trial
Image of M D Anderson Cancer Center in Texas.
M D Anderson Cancer Center
Houston
8Active Trials
15All Time Trials for Cholangiocarcinoma
2014First Cholangiocarcinoma Trial
Top Cities for Cholangiocarcinoma Clinical Trials
Cholangiocarcinoma Clinical Trials by Phase of Trial
Phase < 1 Cholangiocarcinoma Clinical Trials
2Active Cholangiocarcinoma Clinical Trials
2Number of Unique Treatments
2Number of Active Locations
Pneumococcal 13-valent Conjugate VaccineLifestyle Counseling with Emotional Freedom Techniques (EFT)
Cholangiocarcinoma Clinical Trials by Age Group
18+ Cholangiocarcinoma Clinical Trials
104Active Cholangiocarcinoma Clinical Trials
InfigratinibDurvalumabNGM438Neoantigen specific TCR-T cell drug productAZD8205RAIN-32ELU001TT-00420
Most Recent Cholangiocarcinoma Clinical Trials
Top Treatments for Cholangiocarcinoma Clinical Trials
Treatment Name
Active Cholangiocarcinoma Clinical Trials
All Time Trials for Cholangiocarcinoma
First Recorded Cholangiocarcinoma Trial
Gemcitabine
5
41
2002
Nab-paclitaxel
3
6
2015
Infigratinib
2
2
2020
Durvalumab
2
11
2016
TT-00420
2
3
2021
Recently Completed Studies with FDA Approved Treatments for Cholangiocarcinoma
Treatment
Year
Sponsor
MVT-5873
2019
National Cancer Institute (NCI)
M7824
2019
EMD Serono Research & Development Institute, Inc.
FT-2102
2018
Forma Therapeutics, Inc.
ABC294640
2018
RedHill Biopharma Limited
CDX-1140
2017
Celldex Therapeutics
derazantinib
2017
Basilea Pharmaceutica
BGJ398 (infigratinib)
2014
QED Therapeutics, Inc.

What Are Cholangiocarcinoma Clinical Trials?

Cholangiocarcinoma is a type of cancer that occurs in the bile ducts, which are thin tubes transporting bile from the gallbladder and liver to the small intestine. This is a rare type of cancer, and many individuals are diagnosed with it after it spreads progressively outside the ducts.

This cancer is difficult to treat, and the recovery chances are poor. Fortunately, there has been a growing number of clinical trials and research aiming to find an appropriate therapy and treatment for Cholangiocarcinoma.

Why Is Cholangiocarcinoma Being Studied Through Clinical Trials?

Cholangiocarcinoma occurs in around 8,000 individuals in the US every year. This cancer can affect individuals at any age but is most common in older individuals. On average, individuals with Cholangiocarcinoma cancer are around 70 years old.

The lack of treatment options and a cure makes it integral to study this cancer through clinical trials to find therapies and interventions. Most trials aim to find effective and safer treatment strategies to help people with Cholangiocarcinoma.

What Are The Types of Treatments Available For Cholangiocarcinoma?

The treatment is based on the location of Cholangiocarcinoma and whether or not it is spreading. Surgery can be done to treat cancer if it hasn't spread, but in most cases, it has already spread when diagnosed. The common treatment for Cholangiocarcinoma include:

  • Chemotherapy for Bile Duct Cancer
  • Immunotherapy for Bile Duct Cancer
  • Palliative Therapy for Bile Duct Cancer
  • Radiation Therapy for Bile Duct Cancer
  • Surgery for Bile Duct Cancer
  • Targeted Drug Therapy for Bile Duct Cancer

What Are Some Recent Breakthrough Clinical Trials For Cholangiocarcinoma?

2022: The Food and Drug Administration (FDA) has recently given approval to durvalumab given in combination with cisplatin and gemcitabine for Cholangiocarcinoma patients after the breakthrough results in the TOPAZ-1 clinical trial. The study found that including durvalumab in the usual chemotherapy extended the life of the patients. TOPAZ-1 is the first large-scale clinical trial for Cholangiocarcinoma to indicate that immunotherapy treatment could enhance the survival rate of the patients.

2021: FDA approved futibatinib (TAS-120) as a Breakthrough Therapy Designation. It is an FGFR inhibitor that is covalently binding for treating Cholangiocarcinoma patients who have been previously treated for locally metastatic or advanced Cholangiocarcinoma with FGFR2 gene rearrangements. Currently, there is little to no prognosis for this cancer since no treatment isn't any treatment available after the condition fails to improve after chemotherapy. The approval of futibatinib may aid in extending the life of the patients while giving scientists a foundation to find innovative therapies or treatments for Cholangiocarcinoma.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Cholangiocarcinoma Clinical Trials Research?

The Cholangiocarcinoma Foundation: This is a global non-profit institution dedicated to finding a treatment or cure for Cholangiocarcinoma and enhancing the life of the patients. It comprises multiple research groups working in collaboration to enhance information, research, and clinical trials related to Cholangiocarcinoma prognosis, treatment, early detection, prevention, and etiology.

European Network for the Study of Cholangiocarcinoma: This comprises researchers studying this cancer and pursuing clinical trial, translational, and basic research to find therapy and treatment options for Cholangiocarcinoma cancer.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: October 13th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.